134 related articles for article (PubMed ID: 8513661)
1. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
Ford JM; Truman CA; Wilcock GK; Roberts CJ
Clin Pharmacol Ther; 1993 Jun; 53(6):691-5. PubMed ID: 8513661
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: a pilot study.
Forsyth DR; Surmon DJ; Morgan RA; Wilcock GK
Age Ageing; 1989 Jul; 18(4):223-9. PubMed ID: 2683619
[TBL] [Abstract][Full Text] [Related]
3. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
[TBL] [Abstract][Full Text] [Related]
4. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
5. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
7. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.
Allain H; Schück S; Lebreton S; Strenge-Hesse A; Braun W; Gandon JM; Brissot P
Dement Geriatr Cogn Disord; 1999; 10(3):181-5. PubMed ID: 10325444
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease.
Forsyth DR; Wilcock GK; Morgan RA; Truman CA; Ford JM; Roberts CJ
Clin Pharmacol Ther; 1989 Dec; 46(6):634-41. PubMed ID: 2598567
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
10. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
Fontana RJ; Turgeon DK; Woolf TF; Knapp MJ; Foster NL; Watkins PB
Hepatology; 1996 Jun; 23(6):1429-35. PubMed ID: 8675160
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.
Green VJ; Pirmohamed M; Kitteringham NR; Knapp MJ; Park BK
Br J Clin Pharmacol; 1995 Apr; 39(4):411-5. PubMed ID: 7640148
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease.
Mäkelä PM; Truman CA; Ford JM; Roberts CJ
Eur J Clin Pharmacol; 1994; 47(2):151-5. PubMed ID: 7859802
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
Gracon SI
Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
[TBL] [Abstract][Full Text] [Related]
15. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
Grothe DR; Piscitelli SC; Dukoff R; Fullerton T; Sunderland T; Molchan SE
J Clin Psychopharmacol; 1998 Feb; 18(1):78-81. PubMed ID: 9472847
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease: how to give and monitor tacrine therapy.
Woo JK; Lantz MS
Geriatrics; 1995 May; 50(5):50-3. PubMed ID: 7737527
[TBL] [Abstract][Full Text] [Related]
19. Tacrine: first drug approved for Alzheimer's disease.
Crismon ML
Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
[TBL] [Abstract][Full Text] [Related]
20. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
Wood DM; Ford JM; Roberts CJ
Eur J Clin Pharmacol; 1996; 50(1-2):115-9. PubMed ID: 8739821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
